drugset / Trial / NCT04986579
Scalp Cooling in MBC
Phase 2
Recruiting
120 enrolled
Dana-Farber Cancer Institute
AstraZeneca · collabDaiichi Sankyo · collabEisai Inc. · collabGilead Sciences · collabPaxman Coolers Limited · collab
Non-randomizedParallel-groupOpen-labelSupportive care
Summary
This research is being done to compare rates of hair loss of people with metastatic breast who use scalp cooling versus those who do not use scalp cooling after receiving standard of care treatment with either sacituzumab govitecan, trastuzumab deruxtecan, or eribulin. The name of the study intervention involved in this study is: * Paxman Scalp Cooling System
Timeline
- Start
- 2021-10-07
- Primary completion
- 2028-06-01
- Completion
- 2030-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Eribulin | Small molecule | — | Intravenous |
| Background | Sacituzumab Govitecan | Monoclonal antibody | — | Intravenous |
| Background | Trastuzumab deruxtecan | Monoclonal antibody | — | Intravenous |